- Home
- CATX
as 01-17-2025 4:00pm EST
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 782.7M | IPO Year: | N/A |
| Target Price: | $17.25 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.70 - $19.10 | Next Earning Date: | 02-12-2025 |
| Revenue: | $1,557,000 | Revenue Growth: | -73.52% |
| Revenue Growth (this year): | -0.14% | Revenue Growth (next year): | -47.55% |
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HENSON HEIDI | CATX | Director | Dec 4 '24 | Buy | $3.85 | 25,975 | $100,003.75 | 25,975 | |
| Spoor Johan M. | CATX | CEO | Dec 4 '24 | Buy | $3.77 | 8,000 | $30,132.00 | 36,257 | |
| Williamson Robert F III | CATX | Director | Nov 25 '24 | Buy | $3.64 | 6,266 | $22,813.51 | 427,439 | |
| Hunt Jonathan Robert | CATX | Chief Financial Officer | Nov 25 '24 | Buy | $3.74 | 12,829 | $48,974.26 | 48,800 | |
| Spoor Johan M. | CATX | CEO | Nov 25 '24 | Buy | $3.79 | 26,500 | $100,468.00 | 36,257 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
Perspective Therapeutics provides business updates, strategic priorities
GlobeNewswire
6 days ago
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
9 days ago
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
13 days ago
Perspective Therapeutics Appoints Juan Graham as CFO; Shares Fall
GlobeNewswire
13 days ago
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
GlobeNewswire
2 months ago
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
MT Newswires
2 months ago
B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating
TipRanks
2 months ago
Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.